Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HOWL 
Werewolf Therapeutics Inc (HOWL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/07/2025: HOWL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6.83
1 Year Target Price $6.83
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.47% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/07/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 55.82M USD | Price to earnings Ratio - | 1Y Target Price 6.83 |
Price to earnings Ratio - | 1Y Target Price 6.83 | ||
Volume (30-day avg) 6 | Beta 0.73 | 52 Weeks Range 0.59 - 2.38 | Updated Date 11/9/2025 |
52 Weeks Range 0.59 - 2.38 | Updated Date 11/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.62 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.388 | Actual -0.36 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -40.75% | Return on Equity (TTM) -122.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 47349678 | Price to Sales(TTM) 52.22 |
Enterprise Value 47349678 | Price to Sales(TTM) 52.22 | ||
Enterprise Value to Revenue 0.67 | Enterprise Value to EBITDA 0.57 | Shares Outstanding 48540200 | Shares Floating 34170359 |
Shares Outstanding 48540200 | Shares Floating 34170359 | ||
Percent Insiders 5.61 | Percent Institutions 49.55 |
Upturn AI SWOT
Werewolf Therapeutics Inc
Company Overview
History and Background
Werewolf Therapeutics, Inc. is a biopharmaceutical company founded in 2017. It is focused on developing conditionally activated therapeutics engineered to stimulate the patientu2019s immune system for the treatment of cancer. The company's approach involves targeting and activating immune cells specifically within the tumor microenvironment.
Core Business Areas
- Immuno-Stimulatory Therapeutics: Development of novel therapeutics that enhance the body's immune response to fight cancer by specifically activating immune cells within the tumor microenvironment.
Leadership and Structure
The leadership team includes key executives in research and development, business development, and finance. The organizational structure consists of departments focused on drug discovery, preclinical and clinical development, and corporate operations.
Top Products and Market Share
Key Offerings
- VIRALISu2122 platform: A proprietary platform to design and develop novel, conditionally activated INDUKINEu2122 molecules for cancer treatment. Current molecules are in clinical and preclinical trials. Market share and revenue not yet available. Competitors: Other immunotherapy companies developing novel cancer treatments, such as Adaptimmune and Iovance.
- WTX-124: Is an innovative therapeutic candidate targeting solid tumors with promising clinical activity. Market share and revenue not yet available. Competitors: Other immunotherapy companies developing novel cancer treatments.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly in oncology, is characterized by rapid innovation, high competition, and significant investment in research and development. Immunotherapy is a rapidly growing sector within oncology.
Positioning
Werewolf Therapeutics is positioned as an innovative company developing next-generation immunotherapies. Its competitive advantage lies in its VIRALISu2122 platform and its focus on conditionally activated therapeutics.
Total Addressable Market (TAM)
The global oncology market is estimated to be several hundred billion dollars. Werewolf is focused on capturing a segment of the immuno-oncology market. This TAM is expected to keep growing with breakthroughs in cancer treatments.
Upturn SWOT Analysis
Strengths
- Proprietary VIRALISu2122 platform
- Focus on conditionally activated therapeutics
- Experienced leadership team
- Strong intellectual property position
- Novel approach to cancer treatment
Weaknesses
- Early-stage clinical development (high risk)
- Reliance on single technology platform
- Limited commercialization experience
- High cash burn rate
Opportunities
- Potential for partnerships with larger pharmaceutical companies
- Expansion of VIRALISu2122 platform to other disease areas
- Positive clinical trial results
- Growing market for immunotherapies
- Acquisition by larger pharmaceutical company
Threats
- Clinical trial failures
- Competition from other immunotherapy companies
- Regulatory hurdles
- Intellectual property challenges
- Economic downturn impacting funding
Competitors and Market Share
Key Competitors
- NKTR
- AGEN
- ADAP
Competitive Landscape
Werewolf Therapeutics is a smaller player in the immuno-oncology space compared to larger, more established companies. Its advantage lies in its unique VIRALISu2122 platform and focus on conditionally activated therapeutics. However, it faces significant competition and execution risk.
Growth Trajectory and Initiatives
Historical Growth: Werewolf's growth has been primarily driven by progress in its research and development programs.
Future Projections: Future growth is dependent on the success of its clinical trials and potential partnerships. Analyst estimates vary and should be consulted for specific projections.
Recent Initiatives: Recent initiatives include advancing WTX-124 and other INDUKINEu2122 molecules through clinical trials, expanding its VIRALISu2122 platform, and securing partnerships.
Summary
Werewolf Therapeutics is an early-stage biopharmaceutical company with a promising platform for developing conditionally activated immunotherapies. Its strengths lie in its innovative technology and experienced team. However, it faces significant risks associated with clinical development and competition. The company's success depends on positive clinical trial results and strategic partnerships, which are necessary for survival in this type of industry.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Werewolf Therapeutics Inc. Website
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market data and financial information are subject to change. Consult with a qualified financial advisor before making any investment decisions. Market share percentages are estimates based on publicly available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Werewolf Therapeutics Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2021-04-30 | Founder, CEO, President, Secretary & Director Dr. Daniel J. Hicklin Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 46 | Website https://werewolftx.com |
Full time employees 46 | Website https://werewolftx.com | ||
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.